Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 46 to 60 of 114 results for rheumatoid arthritis

  1. Abatacept, adalimumab, etanercept and tocilizumab for treating juvenile idiopathic arthritis (TA373)

    Evidence-based recommendations on abatacept (Orencia), adalimumab (Humira), etanercept (Enbrel) and tocilizumab (RoActemra) for treating juvenile idiopathic arthritis in children, young people and adults.

  2. Rheumatoid arthritis - adalimumab, etanercept and infliximab (sequential use) [ID18]

    Discontinued Reference number: GID-TAG393

  3. Sirukumab for previously treated moderate to severe active rheumatoid arthritis (ID1002)

    Discontinued Reference number: GID-TA10180

  4. Apremilast for treating active psoriatic arthritis (TA433)

    Evidence-based recommendations on apremilast (Otezla) for treating active psoriatic arthritis.

  5. Filgotinib for treating moderately to severely active ulcerative colitis (TA792)

    Evidence-based recommendations on filgotinib (Jyseleca) for moderately to severely active ulcerative colitis in adults when conventional or biological treatment cannot be tolerated, or the disease has responded inadequately or lost response to treatment.

  6. Rituximab for the treatment of rheumatoid arthritis after the failure of conventional disease-modifying anti-rheumatic drugs [ID333]

    Discontinued Reference number: GID-TAG418

  7. Refractory extrapulmonary sarcoidosis: infliximab (ES4)

    Summary of the evidence on infliximab for treating refractory extrapulmonary sarcoidosis to inform local NHS planning and decision-making

  8. Denosumab for the prevention of osteoporotic fractures in postmenopausal women (TA204)

    Evidence-based recommendations on denosumab (Prolia) for preventing osteoporotic fragility fractures in postmenopausal women.

  9. Infliximab for acute exacerbations of ulcerative colitis (TA163)

    Evidence-based recommendations on infliximab (Remicade) for treating acute exacerbations of severely active ulcerative colitis in adults.

  10. Raloxifene for the primary prevention of osteoporotic fragility fractures in postmenopausal women (TA160)

    Evidence-based recommendations on raloxifene for the primary prevention of osteoporotic fragility fractures in postmenopausal women.

  11. Subcutaneous methotrexate:- What is the clinical and cost effectiveness of subcutaneous methotrexate compared with oral methotrexate for adults with early onset RA starting a new DMARD?

    recommendations. Source guidance details Comes from guidance Rheumatoid arthritis in adults: management Number NG100 Date issued

  12. Cox-II inhibitors for the treatment of osteoarthritis and rheumatoid arthritis [ID388]

    Discontinued Reference number: GID-TAG372

  13. Ultrasound in diagnosis:- What is the clinical and cost effectiveness of using ultrasound in addition to clinical assessment when there is uncertainty about the diagnosis in adults with suspected RA?

    RA. Source guidance details Comes from guidance Rheumatoid arthritis in adults: management Number NG100 Date issued

  14. FRAX and QFracture in adults with secondary causes of osteoporosis:- What is the utility of FRAX and QFracture in detecting risk of fragility fracture in adults with secondary causes of osteoporosis?

    risk in patients with causes of secondary osteoporosis other than rheumatoid arthritis and to establish whether their effect on fracture...